Cargando…
Expression of p53 as a biomarker of pazopanib efficacy in solitary fibrous tumours: translational analysis of a phase II trial
BACKGROUND: Solitary fibrous tumours (SFT) are soft tissue sarcomas molecularly defined by the presence of the NAB2::STAT6 intrachromosomal fusion gene. Recently, a prospective phase II trial evaluating the role of the antiangiogenic tyrosine kinase inhibitor pazopanib in SFT has been conducted (NCT...
Autores principales: | Napolitano, Andrea, Moura, David S., Hindi, Nadia, Mondaza-Hernandez, José L, Merino-Garcia, José A., Ramos, Rafael, Dagrada, Gian Paolo, Stacchiotti, Silvia, Graziano, Francesco, Vincenzi, Bruno, Martin-Broto, Javier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364178/ https://www.ncbi.nlm.nih.gov/pubmed/35965642 http://dx.doi.org/10.1177/17588359221116155 |
Ejemplares similares
-
A Comprehensive Review on Solitary Fibrous Tumor: New Insights for New Horizons
por: Martin-Broto, Javier, et al.
Publicado: (2021) -
ISG15 as a prognostic biomarker in solitary fibrous tumour
por: Mondaza-Hernandez, Jose L., et al.
Publicado: (2022) -
Peripheral Inflammatory Indexes Neutrophil/Lymphocyte Ratio (NLR) and Red Cell Distribution Width (RDW) as Prognostic Biomarkers in Advanced Solitary Fibrous Tumour (SFT) Treated with Pazopanib
por: Hidalgo-Ríos, Samuel, et al.
Publicado: (2022) -
A Novel NFIX-STAT6 Gene Fusion in Solitary Fibrous Tumor: A Case Report
por: Moura, David S., et al.
Publicado: (2021) -
Pazopanib as first line treatment for solitary fibrous tumours: the Royal Marsden Hospital experience
por: Maruzzo, Marco, et al.
Publicado: (2015)